Skip to main content
NCBI home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
editorial
. 1998 Jan;90(1):10–12.

Antimicrobial drug resistance among common pathogens in American hospitals: when will the microbe stop winning?

V Idemyor
PMCID: PMC2608303  PMID: 9473923

Full text

PDF
10

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Centers for Disease Control and Prevention (CDC) Nosocomial enterococci resistant to vancomycin--United States, 1989-1993. MMWR Morb Mortal Wkly Rep. 1993 Aug 6;42(30):597–599. [PubMed] [Google Scholar]
  2. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., Tenover F. C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997 Jul;40(1):135–136. doi: 10.1093/jac/40.1.135. [DOI] [PubMed] [Google Scholar]
  3. Knothe H., Shah P., Krcmery V., Antal M., Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection. 1983 Nov-Dec;11(6):315–317. doi: 10.1007/BF01641355. [DOI] [PubMed] [Google Scholar]
  4. Meyer K. S., Urban C., Eagan J. A., Berger B. J., Rahal J. J. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med. 1993 Sep 1;119(5):353–358. doi: 10.7326/0003-4819-119-5-199309010-00001. [DOI] [PubMed] [Google Scholar]
  5. Murray B. E. Problems and mechanisms of antimicrobial resistance. Infect Dis Clin North Am. 1989 Sep;3(3):423–439. [PubMed] [Google Scholar]
  6. Nikaido H. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science. 1994 Apr 15;264(5157):382–388. doi: 10.1126/science.8153625. [DOI] [PubMed] [Google Scholar]
  7. Rice L. B., Willey S. H., Papanicolaou G. A., Medeiros A. A., Eliopoulos G. M., Moellering R. C., Jr, Jacoby G. A. Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother. 1990 Nov;34(11):2193–2199. doi: 10.1128/aac.34.11.2193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Sader H. S., Pfaller M. A., Jones R. N. Prevalence of important pathogens and the antimicrobial activity of parenteral drugs at numerous medical centers in the United States. II. Study of the intra- and interlaboratory dissemination of extended-spectrum beta-lactamase-producing Enterobacteriaceae. Diagn Microbiol Infect Dis. 1994 Dec;20(4):203–208. doi: 10.1016/0732-8893(94)90004-3. [DOI] [PubMed] [Google Scholar]
  9. Salyers A. A., Speer B. S., Shoemaker N. B. New perspectives in tetracycline resistance. Mol Microbiol. 1990 Jan;4(1):151–156. doi: 10.1111/j.1365-2958.1990.tb02025.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES